Contineum Therapeutics Inc (CTNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 77,230 | 16,264 | 15,526 | 0 | 0 |
| Marketable Securities | 141,423 | 101,643 | 109,664 | 0 | 0 |
| TOTAL | $220,320 | $119,711 | $127,706 | $0 | $0 |
| Non-Current Assets | |||||
| PPE Net | 801 | 756 | 678 | N/A | N/A |
| Other Non-Current Assets | 234 | 3,097 | 2,002 | 0 | 0 |
| TOTAL | $1,035 | $3,853 | $2,680 | $N/A | $N/A |
| Total Assets | $221,355 | $123,564 | $130,386 | $0 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 464 | 0 | 0 |
| Accounts payable and accrued liabilities | 734 | 570 | 635 | 0 | 0 |
| Accrued Expenses | 2,521 | 5,190 | 4,385 | 0 | 0 |
| TOTAL | $3,739 | $6,234 | $5,484 | $0 | $0 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 113 | 192,959 | 192,838 | 0 | 0 |
| TOTAL | $113 | $192,959 | $192,838 | $N/A | $N/A |
| Total Liabilities | $3,852 | $199,193 | $198,322 | $0 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 25,723 | 25,723 | N/A | N/A | N/A |
| Common Shares | 26 | 2 | 2 | 0 | 0 |
| Retained earnings | -92,570 | -83,561 | -75,144 | 0 | 0 |
| Other shareholders' equity | -127 | -58 | 108 | 0 | 0 |
| TOTAL | $217,503 | $-75,629 | $-67,936 | $0 | $0 |
| Total Liabilities And Equity | $221,355 | $123,564 | $130,386 | $0 | $0 |